A piece in prostate cancer puzzle: Future perspective of novel molecular signatures
| Autor: | Anmar M. Nassir |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0106 biological sciences
0301 basic medicine Oncology PCA3 medicine.medical_specialty urologic and male genital diseases 01 natural sciences Article 03 medical and health sciences Prostate cancer Prostate Internal medicine Diagnosis Medicine lcsh:QH301-705.5 Future perspective business.industry Cancer Prognosis medicine.disease Prostate Stem Cell Antigen Urokinase receptor Prostate-specific antigen 030104 developmental biology medicine.anatomical_structure lcsh:Biology (General) Screening General Agricultural and Biological Sciences business Biomarkers 010606 plant biology & botany |
| Zdroj: | Saudi Journal of Biological Sciences, Vol 27, Iss 4, Pp 1148-1154 (2020) Saudi Journal of Biological Sciences |
| Popis: | Prostate cancer (PCa) has a variable biological potential. It constitutes the second most common cancer amongst men worldwide and the fifth most common cancer in Saudi Arabia. Identifying men at higher risk of developing PCa, differentiating indolent from aggressive disease and predicting the likelihood of progression will improve decision-making and selection for active surveillance protocols. Biomarkers have been utilized for PCa screening and predicting cancer behavior and response to treatment. The prostate specific antigen (PSA) screening helps detect PCa in early stages, while implementing a plan for management and outcome. However, PSA screening is still controversial, due to the risks of over diagnosis and treatment, and its inability to detect a good proportion of advanced tumors. Alternatively, a new era of PCa biomarkers has emerged with higher PCa specificity than PSA and its isoforms hopefully improving screening methods, such as Prostate Health Index (PHI) score, Progensa Prostate Cancer Antigen 3 (PCA3), Mi-Prostate Score (MiPS), Prostate Stem Cell Antigen (PSCA), 4Kscore test, and Urokinase Plasminogen Activation (uPA and uPAR). Few novel biomarkers have shown promise in preliminary results. This review will display promising biomarkers including some important FDA approved ones, highlighting their clinical implication and future place in the PCa puzzle, along with addressing their current limitations. Keywords: Prostate cancer, Biomarkers, Diagnosis, Screening, Prognosis |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|